Program
exaluren
Also written as “ELX-02” and “Exaluren”.
Its studies are mostly in Genetic Diseases, Inborn · Nephritis, Hereditary · Cystic Fibrosis · Renal Insufficiency · Cystinosis, led by Eloxx Pharmaceuticals.
Furthest: phase 2, since Aug 16, 20199 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eloxx Pharmaceuticals | 91 open or running | phase 2since Aug 16, 2019 | Jun 10, 2016 | Jun 30, 2027phase 2 · NCT07523581 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 10, 2016First study: phase 1 study in Genetic Diseases, InbornFirst studyNCT02807961 · 42 enrolled
- Aug 30, 2017Phase 1 study in Genetic Diseases, InbornNCT03292302 · 18 enrolled · Belgium
- Oct 10, 2017Phase 1 study in Genetic Diseases, InbornNCT03309605 · 62 enrolled · Belgium
- Dec 4, 2018Phase 1 study in Renal InsufficiencyNCT03776539 · 24 enrolled · United States
- Aug 16, 20193 phase 2 studiesNCT04135495, NCT04126473, NCT04069260
- Jun 29, 2022Phase 2 study in Nephritis, HereditaryNCT05448755 · 3 enrolled · Australia, United Kingdom
- Apr 5, 2026Phase 2 study in Nephritis, HereditaryNCT07523581 · 24 planned · United States, United Kingdom
Ahead
- Jun 30, 2027Primary completion: phase 2 study in Nephritis, HereditaryNCT07523581
TargetBeta
FAU →RPL10 →RPL10A →RPL11 →RPL12 →RPL13 →RPL13A →RPL14 →RPL15 →RPL17 →RPL18 →RPL18A →RPL19 →RPL21 →RPL22 →RPL23 →RPL23A →RPL24 →RPL26 →RPL27 →RPL27A →RPL28 →RPL29 →RPL3 →RPL30 →RPL31 →RPL32 →RPL34 →RPL35 →RPL35A →RPL36 →RPL36A →RPL37 →RPL37A →RPL38 →RPL39 →RPL4 →RPL41 →RPL5 →RPL6 →RPL7 →RPL7A →RPL8 →RPL9 →RPLP0 →RPLP1 →RPS10 →RPS11 →RPS12 →RPS13 →RPS14 →RPS15 →RPS15A →RPS16 →RPS17 →RPS18 →RPS19 →RPS2 →RPS20 →RPS21 →RPS23 →RPS24 →RPS25 →RPS26 →RPS27 →RPS27A →RPS28 →RPS29 →RPS3 →RPS3A →RPS4X →RPS4Y1 →RPS5 →RPS6 →RPS7 →RPS8 →RPS9 →RPSA →read by rule
“80S Ribosome modulator”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07523581Nephritis, Hereditary · United States, United Kingdom | 2 | Recruiting | Jun 30, 2027 | 24 |
| NCT05448755Nephritis, Hereditary · Australia, United Kingdom | 2 | Completed | Sep 11, 2023 | 3 |
| NCT04135495Cystic Fibrosis · United States, Canada | 2 | Completed | Oct 3, 2022 | 17 |
| NCT04126473Cystic Fibrosis · Australia, Germany, Israel | 2 | Completed | Apr 6, 2022 | 17 |
| NCT04069260Genetic Diseases, Inborn · Canada | 2 | Terminated | Dec 17, 2019 | 3 |
| NCT03776539Renal Insufficiency · United States | 1 | Completed | Jul 30, 2019 | 24 |
| NCT03309605Genetic Diseases, Inborn · Belgium | 1 | Completed | Jun 17, 2019 | 62 |
| NCT03292302Genetic Diseases, Inborn · Belgium | 1 | Completed | Dec 15, 2017 | 18 |
| NCT02807961Genetic Diseases, Inborn | 1 | Terminated | Feb 2017 | 42 |
How it is read
Names in the registry
- “ELX-02”, 8 entries
- “Exaluren”, 1 entry
Conditions, from the studies’ own filings
- Genetic Diseases, Inborn, 3 studies
- Nephritis, Hereditary, 2 studies
- Cystic Fibrosis, 2 studies
- Renal Insufficiency, 1 study
- Cystinosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.